<DOC>
	<DOC>NCT01631227</DOC>
	<brief_summary>Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.</brief_summary>
	<brief_title>Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Eprosartan</mesh_term>
	<criteria>Inclusion Criteria Males or females with essential hypertension, blood pressure values between 140 mmHg and 179 mmHg systolic and between 90 mmHg and 109 mmHg diastolic Given written informed consent prior to starting the study Exclusion Criteria Women with childbearing potential, breast feeding or pregnant; Inability to discontinue all prior antihypertensive medication; Secondary hypertension Severe hypertension Severe diabetes mellitus (HbA1c greater 8.5%)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>